BioSpace News Archive

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported its operating and financial results for the quarter ended September 30, 2019.

Provention Bio, Inc. announced the European Medicines Agency has granted PRV-031 PRIority MEdicines designation for the prevention or delay of clinical type 1 diabetes in individuals at-risk of developing the disease.

Pepticom, a leader in artificial intelligence peptide drug discovery, announced today that it has secured $5 million in Series A funding from the Chartered Group.

AVROBIO, Inc., announced that the U.S. Food and Drug Administration has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease.

Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma

Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN007 data on clinical safety and efficacy in solid tumor patients at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference to be held in Boston, MA on October 26-30, 2019.

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced the appointment of Dr. Oren Hershkovitz as Chief Executive Officer, effective November 16, 2019.

Bristol-Myers Squibb Company announced that the European Commission has approved Opdivo flat dosing schedule of 240 mg infused over 30 minutes every two weeks or 480 mg infused over 60 minutes every four weeks for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.